TrialInvestigational new drugs2014

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.

Jonathan E Rosenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.